PULMONARY EDEMA THERAPEUTICS MARKET ANALYSIS
Recent product launches and approvals is expected to boost global pulmonary edema therapeutics market growth. For instance, on May 5, 2020, Farxiga (dapagliflozin), an oral tablet developed by AstraZeneca, a global biopharmaceutical company, was approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with reduced ejection fraction. Heart failure is a severe condition, which leads to cardiogenic pulmonary edema. These factors are expected to support global pulmonary edema therapeutics market growth over the forecast period.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
